Home » Research » Publications
SARC provides expert biostatistical support and administrative support to assist with clinical trials publications on drug activity, survival, and toxicities. A sampling of publications are provided here. Other publications supported by SARC describe: 1) insights from post-study (“post-hoc”) analyses of clinical trials data, imaging, and biomaterials; 2) pilot studies; and 3) career development projects.
Year
Trial
Title / pubmed.gov
Journal
Sarcoma Subtype
First Author
2024
SARC032
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial – ScienceDirect
The Lancet
Soft tissue sarcoma of the extremities
Mowery
2023
SARC021
Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
Clinical Cancer Research
Soft tissue sarcoma
Cramer
2022
SARC024
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Cancer Medicine
Ewing Sarcoma
Attia
2021
SARC025
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
Cancer
Chugh
2020
Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial
Journal of Geriatric Oncology
Locally advanced or metastatic soft tissue sarcoma
Younger
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study
The Oncologist
Refractory Liposarcoma
Riedel
SARC028
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma
Keung
B cells are associated with survival and immunotherapy response in sarcoma
Nature
Petitprez
2019
SARC018
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy
Sarcoma
Metastatic Leiomyosarcoma
Choy
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Journal of Clinical Oncology
Osteogenic Sarcoma
Davis
2018
SARC009
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib
JAMA Oncology
Advanced Gastrointestinal Stromal Tumors
Schuetze
2017
SARC006
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naïve Malignant Peripheral Nerve Sheath Tumors
Malignant peripheral nerve sheath tumors sporadic or NF1 associated
Higham
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
Alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
The Lancet, Oncology
Tap
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Tawbi
2016
SARC009: Phase 2 Study of Dasatinib in Patients With Previously Treated, High-Grade, Advanced Sarcoma
Leiomyosarcoma, liposarcoma, MFH/pleomorphic undifferentiated sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, osteosarcoma (skeletal or extraosseous), chondrosarcoma, ewing’s, alveolar soft part sarcoma, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma/solitary fibrous tumor, gastrointestinal stromal tumors (GIST)
SARC011
Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival
Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma
Koshkin
2014
A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas
Pappo
2013
SARC005
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC005)
Uterine Leiomyosarcoma
Hensley
2012
SARC003
Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003
Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
Fox
2010
SARC001
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
Desmoid tumors
2009
Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
Ewing’s Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcom, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only)
2007
SARC002
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
Unresectable soft tissue sarcoma
Maki